TERTIARY LYMPHOID STRUCTURES AS MARKERS OF ANTI-TUMOR IMMUNITY WITH INDEPENDENT PROGNOSTIC VALUE IN THE PORTEC-3 TRIAL OF HIGH-RISK ENDOMETRIAL CANCER

被引：0

作者：

Horeweg, N. ^{[1
]}

Workel, H. ^{[2
]}

Loiero, D. ^{[3
]}

Church, D. ^{[4
]}

Vermij, L. ^{[5
]}

Leon-Castillo, A. ^{[5
]}

De Boer, S. ^{[1
]}

Nout, R. ^{[1
,6
]}

Powell, M. ^{[7
]}

Mileshkin, L. ^{[8
]}

Mackay, H. ^{[9
]}

Leary, A. ^{[10
]}

Singh, N. ^{[11
]}

Jurgenliemk-Schulz, I. ^{[12
]}

Creutzberg, C. L. ^{[1
]}

Kolzer, V. ^{[3
,13
,14
]}

Nijman, H. W. ^{[2
]}

Bosse, T. ^{[15
]}

De Bruyn, M. ^{[2
]}

机构：

[1] Leiden Univ Med Ctr LUMC, Dept Radiat Oncol, Leiden, Netherlands

[2] Univ Med Ctr Groningen, Dept Obstet & Gynaecol, Gynaecol Oncol, Groningen, Netherlands

[3] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland

[4] Wellcome Trust Ctr Human Genet, London, England

[5] Leiden Univ Med Ctr LUMC, Dept Pathol, Leiden, Netherlands

[6] Erasmus MC Canc Inst, Dept Radiotherapy, Rotterdam, Netherlands

[7] Barts Hlth NHS Trust, Dept Clin Oncol, London, England

[8] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Med Oncol & Haematol, Toronto, ON, Canada

[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[11] Barts Hlth NHS Trust, Dept Pathol, London, England

[12] UMC Utrecht, Dept Radiat Oncol, Utrecht, Netherlands

[13] Univ Oxford, Dept Oncol, Oxford, England

[14] Nuffield Dept Med, Oxford, England

[15] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷

关键词：

D O I：

10.1136/ijgc-2021-ESGO.156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

482

引用

页码：A99 / A101

页数：3

共 36 条

[1] PROGNOSTIC RELEVANCE OF THE MOLECULAR CLASSIFICATION IN HIGH-RISK ENDOMETRIAL CANCER: ANALYSIS OF THE PORTEC-3 TRIAL
Leon-Castillo, A.
de Boer, S. M.
Powell, M. E.
Mileshkin, L. R.
Mackay, H. J.
Leary, A.
Nijman, H. W.
Singh, N.
Pollock, P.
Bessette, P.
Haie-Meder, C.
Smit, V. T. H. B. M.
Edmondson, R. J.
Putter, H.
Kitchener, H. C.
Crosbie, E. J.
de Bruyn, M.
Nout, R. A.
Horeweg, N.
Bosse, T.
Creutzberg, C. L.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A7 - A8
[2] Clinical Implications of the PORTEC-3 Trial for the Treatment of High-Risk Endometrial Cancer
Waltar, Till
Marnitz, Simone
STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (04) : 410 - 413
[3] Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
Creutzberg, C. L.
Leon-Castillo, A.
de Boer, S. M.
Powell, M. E.
Mileshkin, L. R.
Mackay, H. J.
Leary, A.
Nijman, H. W.
Singh, N.
Pollock, P.
Fyles, A.
Haie-Meder, C.
Smit, V. T. H. B. M.
Edmondson, R. J.
Putter, H.
Kitchener, H. C.
Crosbie, E. J.
de Bruyn, M.
Nout, R.
Bosse, T.
ANNALS OF ONCOLOGY, 2019, 30 : 899 - +
[4] Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer
de Boer, S.
Powell, M. E.
Mileshkin, L.
Katsaros, D.
Bessette, P.
Haie-Meder, C.
Ottevanger, P. B.
Ledermann, J. A.
Khaw, P.
Colombo, A.
Fyles, A.
Baron, M. H.
Jurgenliemk-Schulz, I.
Kitchener, H.
Nijman, H. W.
Kruitwagen, R. F.
Smit, V. T.
Nout, R. A.
Putter, H.
Creutzberg, C. L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S1 - S2
[5] Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
de Boer, S. M.
Wortman, B. G.
Bosse, T.
Powell, M. E.
Singh, N.
Hollema, H.
Wilson, G.
Chowdhury, M. N.
Mileshkin, L.
Pyman, J.
Katsaros, D.
Carinelli, S.
Fyles, A.
McLachlin, C. M.
Haie-Meder, C.
Duvillard, P.
Nout, R. A.
Verhoeven-Adema, K. W.
Putter, H.
Creutzberg, C. L.
Smit, V. T. H. B. M.
ANNALS OF ONCOLOGY, 2018, 29 (02) : 424 - 430
[6] MOLECULAR PROFILING OF NSMP HIGH-RISK ENDOMETRIAL CANCERS OF THE PORTEC-3 TRIAL - PROGNOSTIC REFINEMENT AND DRUGGABLE TARGETS
Vermij, L.
Powell, M.
Leon-Castillo, A.
De Boer, S.
Mileshkin, L.
Mackay, H.
Leary, A.
Nijman, H. W.
Singh, N.
Pollock, P.
Bessette, P.
Haie-Meder, C.
Smit, V.
Edmondson, R.
Crosbie, E.
Nout, R.
Horeweg, N.
Creutzberg, C. L.
Bosse, T.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A89 - A90
[7] Upfront pathology review in the randomised PORTEC-3 trial for high risk endometrial cancer
de Boer, S.
Wortman, B.
Bosse, T.
Powell, M. E.
Singh, N.
Hollema, H.
Wilson, G.
Chowdhury, M.
Mileshkin, L.
Pyman, J.
Katsaros, D.
Carinelli, S.
Fyles, A.
McLachlin, C. M.
Haie-Meder, C.
Duvillard, P.
Nout, R.
Verhoeven-Adema, K.
Putter, H.
Creutzberg, C.
Smit, V.
VIRCHOWS ARCHIV, 2017, 471 : S13 - S13
[8] Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer
Post, Cathalijne C. B.
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Leary, Alexandra
Ottevanger, Nelleke P.
McCormack, Mary
Khaw, Pearly
D'Amico, Romerai
Fyles, Anthony
Chargari, Cyrus
Kitchener, Henry C.
Nijman, Hans W.
Lutgens, Ludy
Jurgenliemk-Schulz, Ina M.
Nout, Remi A.
Putter, Hein
Horeweg, Nanda
Bosse, Tjalling
Creutzberg, Carien L.
RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1122 - S1124
[9] Prognostic value of PORTEC-3 molecular markers by disease risk in a real-world early endometrial cancer cohort.
Dow, Jessica
Kolli, Sahiti
Karalius, Brad
Shami, Jessica
Khosla, Sajan
Roy, David
Mayer, Ingrid A.
Dempster, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Leon-Castillo, Alicia
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda R.
Mackay, Helen J.
Leary, Alexandra
Nijman, Hans W.
Singh, Naveena
Pollock, Pamela M.
Bessette, Paul
Fyles, Anthony
Haie-Meder, Christine
Smit, Vincent T. H. B. M.
Edmondson, Richard J.
Putter, Hein
Kitchener, Henry C.
Crosbie, Emma J.
de Bruyn, Marco
Nout, Remi A.
Horeweg, Nanda
Creutzberg, Carien L.
Bosse, Tjalling
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29) : 3388 - +

← 1 2 3 4 →